Drug Shortages due to Brexit: EU gives Answers
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
If the United Kingdom (UK) leaves the European Union (EU) without a withdrawal agreement ("no deal scenario" or "hard brexit"), EU law will no longer apply in the UK. In this case, companies carrying out certain activities in the UK will have to make changes in order to to comply with EU law and continue to supply medicines in the EU.
The EMA has now published a question-and-answer document and points out that in the event of a withdrawal agreement, there will be a transitional period during which EU law will continue to apply in the UK. This should ensure that access to medicines is not compromised.
The questions and answers explain how the EMA, the European Commission and the EU/EEA Member States have been working closely together since May 2017 to advise companies on how to apply for the necessary changes to minimise the impact on the supply of medicines.
This document applies to both human and veterinary medicines and will be updated as necessary.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?